Re­searchers spot­light a bas­ket of 'good' re­sponse rates for the next ADC in Seat­tle Ge­net­ic­s' pipeline

In Au­gust 2017, Seat­tle Ge­net­ics opt­ed in­to a de­vel­op­ment part­ner­ship for an an­ti­body-drug con­ju­gate de­vel­oped by Gen­mab as part of a col­lab­o­ra­tion sev­en years in the mak­ing. A year and a half lat­er, re­searchers have pulled the cur­tain back on some ear­ly re­sults that might jus­ti­fy their en­thu­si­asm for ti­so­tum­ab ve­dotin.

In a Phase I/II tri­al in­volv­ing 147 pa­tients — span­ning 6 dif­fer­ent can­cer types — who have be­come re­sis­tant to an av­er­age of three types of pri­or treat­ments, the ADC is found to yield re­spons­es in a “sig­nif­i­cant mi­nor­i­ty,” mean­ing their tu­mors ei­ther shrank or stopped grow­ing. The re­spons­es last­ed an av­er­age of 5.7 months, with the top of the range reach­ing 9.5 months, ac­cord­ing to the re­search team at The In­sti­tute of Can­cer Re­search, Lon­don, and The Roy­al Mars­den NHS Foun­da­tion Trust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER